Skip to main content

Search

Reset all filters
69 Result(s)
Sort by

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction
JARDIANCE® (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction

JARDIANCE® (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction

JARDIANCE® is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death and hospitalization for chronic heart failure1 Heart failure represents a significant, growing disease burden
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
COACH Program

COACH Program

The COACH Program addresses the unique needs of people living with heart failur and it's yielding promising results across Ontario. Find out more.
AHEAD Program

AHEAD Program

The partnership program led by Boehringer Ingelheim Canada to address gaps in Canada’s health system for people living with T2D and heart failure. Click to read more.
Science Stories

Science Stories

Science and Innovation - Human Health Innovation - Science Stories
Medly Program

Medly Program

Learn more about the Medly Program and the partnership between Toronto’s UHN and Boehringer Ingelheim Canada to expand it to additional communities.
CONTINUUM

CONTINUUM

CONTINUUM, a collaborative project, investigates how digital technology can help healthcare professionals manage complex patient cases at home. Keep reading.
Global Careers Page

Global Careers Page

Join a global team of more than 52,000 passionate and talented individuals dedicated to improving the health of humans and animals worldwide.